Metroka CE, Josefberg H; International Conference on AIDS.
Int Conf AIDS. 1989 Jun 4-9; 5: 242 (abstract no. M.B.P.126).
St. Luke's/Roosevelt Hospital Center, New York, NY, USA
OBJECTIVE: An open study of the efficacy of high dose acyclovir in the prevention of invasive CMV. METHODS: We studied 60 patients (pts) who were at high risk for CMV from 12/87 to 1/30/89. All pts had less than 150 T4+ cells/mm3. RESULTS: The mean T4+ cells at the time of treatment initiation was 75 (range, 4 to 146). 30 pts also received AZT and dapsone, 16 pts received AZT and bactrim, 9 pts received AZT and aerosolized pentamidine, 3 pts received aerosolized pentamidine, and 2 pts received dapsone alone. The mean duration of follow-up was 6.25 mos (range up to 13 mos). During this time no pts receiving 800 mg of acyclovir q4h developed clinical, histological, or virological evidence of CMV. In contrast 3 of 9 pts who refused treatment developed evidence of invasive CMV. 3 pts treated with acyclovir died during the period of observation; none of these with evidence of CMV. CONCLUSION: This study raises the possibility that acyclovir may be useful as prophylaxis for CMV. Further longitudinal studies will be necessary to determine the efficacy of this treatment.
Publication Types:
Keywords:
- Acyclovir
- Dapsone
- Heart Transplantation
- Humans
- Immunization, Passive
- Immunosuppression
- Kidney Transplantation
- Liver Transplantation
- Longitudinal Studies
- Pentamidine
- Transplantation, Homologous
- Zidovudine
- prevention & control
- surgery
- therapy
- transplantation
Other ID:
UI: 102176980
From Meeting Abstracts